Latigo Biotherapeutics, Inc.(LTGO)
$13.11+0.18 (+1.39%)
LTGO
Latigo Biotherapeutics, Inc. financials statements
$13.11
At close:+0.18 (+1.39%)
Latigo Biotherapeutics, Inc. (LTGO) Ratios
39 Followers
Latigo Biotherapeutics, Inc. Ratios
LTGO's free cash flow for Q3 2026 was $-19.56M. For the 2026 fiscal year, LTGO's free cash flow was decreased by $-36.00K and operating cash flow was $-19.52M. See a summary of the company’s cash flow.
| Ratios | Dec 25 |
|---|---|
| Liquidity Ratios | |
| Current Ratio | 4.00 |
| Quick Ratio | 4.00 |
| Cash Ratio | 3.76 |
| Solvency Ratio | -0.35 |
| Operating Cash Flow Ratio | -5.29 |
| Short-Term Operating Cash Flow Coverage | 0.00 |
| Net Current Asset Value | $ -233.36M |
| Leverage Ratios | |
| Debt-to-Assets Ratio | 0.01 |
| Debt-to-Equity Ratio | -0.00 |
| Debt-to-Capital Ratio | -0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 |
| Financial Leverage Ratio | -0.33 |
| Debt Service Coverage Ratio | 0.00 |
| Interest Coverage Ratio | 0.00 |
| Debt to Market Cap | 0.00 |
| Interest Debt Per Share | 0.02 |
| Net Debt to EBITDA | 0.62 |
| Profitability Margins | |
| Gross Profit Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Profit Margin | 0.00% |
| Pretax Profit Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Continuous Operations Profit Margin | 0.00% |
| Net Income Per EBT | 100.00% |
| EBT Per EBIT | 98.89% |
| Return on Assets (ROA) | -144.56% |
| Return on Equity (ROE) | 47.12% |
| Return on Capital Employed (ROCE) | -193.43% |
| Return on Invested Capital (ROIC) | -191.54% |
| Return on Tangible Assets | -144.56% |
| Earnings Yield | -13.61% |
| Efficiency Ratios | |
| Receivables Turnover | 0.00 |
| Payables Turnover | 0.00 |
| Inventory Turnover | 0.00 |
| Fixed Asset Turnover | 0.00 |
| Asset Turnover | 0.00 |
| Working Capital Turnover Ratio | 0.00 |
| Cash Conversion Cycle | 0.00 |
| Days of Sales Outstanding | 0.00 |
| Days of Inventory Outstanding | 0.00 |
| Days of Payables Outstanding | 0.00 |
| Operating Cycle | 0.00 |
| Cash Flow Ratios | |
| Operating Cash Flow Per Share | -2.22 |
| Free Cash Flow Per Share | -2.22 |
| Dividend Paid and CapEx Coverage Ratio | -717.33 |
| Capital Expenditure Coverage Ratio | -717.33 |
| Operating Cash Flow Coverage Ratio | -141.39 |
| Operating Cash Flow to Sales Ratio | 0.00 |
| Free Cash Flow Yield | -12.18% |
| Valuation Ratios | |
| Price-to-Earnings (P/E) Ratio | -7.36 |
| Price-to-Sales (P/S) Ratio | 0.00 |
| Price-to-Book (P/B) Ratio | -3.46 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -8.21 |
| Price-to-Operating Cash Flow Ratio | -8.22 |
| Price-to-Earnings Growth (PEG) Ratio | 0.00 |
| Enterprise Value Multiple | -6.66 |
| Enterprise Value | 733.49M |
| EV to EBITDA | -6.66 |
| EV to Sales | 0.00 |
| EV to Free Cash Flow | -7.51 |
| EV to Operating Cash Flow | -7.52 |
| Tangible Book Value Per Share | -5.27 |
| Shareholders’ Equity Per Share | -5.27 |
| Tax and Other Ratios | |
| Effective Tax Rate | 0.00 |
| Revenue Per Share | 0.00 |
| Net Income Per Share | -2.48 |
| Tax Burden | 1.00 |
| Interest Burden | 0.99 |
| Research & Development to Revenue | 0.00 |
| SG&A to Revenue | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 |
| Income Quality | 0.89 |
Currency in USD
